• Publications
  • Influence
GlaxoSmithKline Forms US$650 M Epigenetics Alliance with Epizyme
Epizyme, which was formed in 2007, has signed its first major deal, a global epigenetics alliance with GlaxoSmithKline, which will leverage the company’s HMT discovery platform to develop and commercialise novel small molecule HMT therapeutics for cancer and other diseases. Expand
BMS/Ambrx Deal Highlights Big Pharma’s Growing Interest in Protein Drug Engineering
Bristol-Myers Squibb has partnered with Ambrx for the development and commercialisation of derivatives of fibroblast growth factor 21 (FGF-21) for the potential treatment of type 2 diabetes andExpand
Pfizer Becomes BIND Therapeutics’ Second Major Nanomedicine Collaborator
BIND Therapeutics has formed a collaboration with Pfizer to utilise its Medicinal Nanoengineering platform to develop and commercialise multiple Accurins using select small molecule targeted therapies supplied by Pfizer. Expand
A Review of Deal Making in 2012
Deal activity in the pharmaceutical industry fell notably in 2012 as partnering strategies became increasingly focused and R&D budgets remained constrained. Mean deal values increased from 2011,Expand
Merck & Co. Joins Forces with Roche for Promotion of Victrelis™
The partnership will strengthen Merck’s position in the HCV drug market as it competes with Vertex Pharmaceuticals’ Incivek™ (telaprevir), which also gained US FDA approval in May 2011 and is regarded as having a better efficacy and tolerability profile. Expand
Pfizer Mitigates Tanezumab Risk with Potential US$1.8 B Deal with Eli Lilly
Pfizer hopes to resume studies of the anti-NGF antibody tanezumab in osteoarthritis, chronic low back pain and cancer pain after submitting nonclinical data to the FDA in the first half of 2014. Expand
Merck & Co. Out-Licenses Second CNS Programme to Cerecor
Cerecor has signed a second licensing deal with Merck & Co., this time gaining global rights to Merck’s small molecule NMDA (N-methyl-D-aspartate) receptor subunit 2B (NR2B) antagonist MK-0657 (nowExpand